Related Experiment Video
Updated: May 18, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Prevention of multiple sclerosis: a realistic goal?]
1Service de neurologie A et fondation Eugène Devic EDMUS pour la sclérose en plaques, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59 boulevard Pinel, Lyon-Bron cedex, France. sandra.vukusic@chu-lyon.fr
Revue Neurologique
|September 20, 2012
Summary
Multiple sclerosis (MS) is a growing cause of neurological disability. Identifying early signs and understanding genetic and environmental factors could enable primary prevention strategies for MS.
Area of Science:
- Neurology
- Immunology
- Genetics
Context:
- Multiple sclerosis (MS) is a leading cause of chronic neurological disability in Western nations, with rising incidence and prevalence.
- Subtle, preclinical manifestations of MS, including radiological, biological, and immunological endophenotypes, exist before overt clinical symptoms.
- Understanding the prodromal phase is crucial for early detection and intervention.
Purpose:
- To explore the potential for identifying preclinical markers of multiple sclerosis.
- To investigate the role of genetic and environmental factors in the aetiology of MS.
- To pave the way for primary prevention strategies for MS.
Summary:
- MS presents with a preclinical phase detectable through specific endophenotypes.
- Research into genetic and environmental triggers is essential for understanding MS aetiology.
- Early identification of MS risk factors may facilitate future prevention efforts.
Impact:
- Advances in understanding MS aetiology and progression.
- Potential for developing novel diagnostic tools for early MS detection.
- Foundation for future primary prevention strategies to reduce MS burden.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...